Antibody-targeted therapy for chronic rejection after kidney transplant
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You had a kidney transplant at least 6 months ago.
- Your kidney function is at least 30% of normal (eGFR 30 or higher).
- You are already on a stable anti-rejection medication plan (tacrolimus or cyclosporine, mycophenolate, and prednisone) for at least 4 weeks.
- You have a specific type of antibody in your blood that attacks your kidney (called donor-specific antibodies).
- A kidney biopsy confirmed you have chronic active antibody-mediated rejection.
- You are not a carrier of a certain genetic variant that would cause problems with azathioprine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called CID-103 to treat antibody-mediated rejection (ABMR), a type of immune response that damages transplanted kidneys. The drug targets immune cells that attack the transplant, and researchers hope it may help preserve kidney function and prevent transplant failure.
This trial tests a new drug called SG301 for people whose kidney transplant is being rejected by their own antibodies (antibody-mediated rejection, or AMR). The drug targets a protein on antibody-producing cells to help stop the rejection and protect the transplanted kidney.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
This study tests a new medicine called mezagitamab for people whose kidney transplant is being rejected by their immune system (a condition called antibody-mediated rejection). The goal is to see if it can help stop the rejection and protect the transplanted kidney.
This trial tests whether belatacept can help prevent damage in kidney transplant recipients who develop new antibodies against their donor kidney. It is for people whose kidney function is still stable, which may allow treatment to slow or stop antibody-related injury.
Hear when a new Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.